Germany's vaccine commission said the AstraZeneca coronavirus vaccine should not be given to people older than 65 years.

'AstraZeneca vaccine shouldn't be given to over-65s', says Germany's vaccine commission

AstraZeneca Plc has informed European Union officials on Friday it would cut deliveries of its COVID-19 vaccine to the bloc by 60 per cent to 31 million doses in the first quarter of the year due to production problems, a senior official told Reuters.

AstraZeneca to cut COVID-19 vaccine delivery to EU by 60%: Report

Brazil`s health regulator Anvisa said late on Saturday it had approved the import of 2 million doses of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, although the jab is not yet approved for use in the country.

Brazil to import two million AstraZeneca vaccine doses, not yet approved for use

Union Minister Prakash Javadekar on Saturday said that Indian government had approved emergency use of AstraZeneca/ Oxford University coronavirus vaccine, also known as Covishield in India. The minister said that the government had given a go-ahead on Friday.

India: AstraZeneca COVID-19 vaccine approved for emergency use

British regulators have approved the AstraZeneca-Oxford vaccine as the country looks to accelerate its inoculation campaign. But Indian regulators have sought more data from the makers of the jab. WION's Palki Sharma has the full report.

Gravitas: Britain approves Astrazeneca-Oxford vaccine

Astra and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.

Astrazeneca likely to run additional global covid-19 vaccine trial

Prime Minister Narendra Modi will visit the Pune-based Serum Institute of India on November 28, a senior official said on Thursday. The Serum Institute of India, the world's largest manufacturer of vaccines by volume, has partnered with global pharma giant AstraZeneca and Oxford University for the COVID-19 vaccine.

Coronavirus vaccine tracker: PM Modi to visit Serum Institute of India on November 28

The dose of AstraZeneca Plc's Covid antibody that demonstrated the most significant level of adequacy was tried in a more youthful populace than a greater portion that indicated less viability, as per the top of the US Activity Warp Speed program.

90% efficacy of Oxford's coronavirus vaccine came from younger group

AstraZeneca has announced that its vaccine candidate has shown an average efficacy of about 70% , The vaccine candidate has been developed along with the Oxford. The potential vaccine against the novel coronavirus maybe around 90 percent effective, the company said citing interim analysis of results from late-stage clinical trials.

Oxford-AstraZeneca coronavirus vaccine shows 70% efficacy

Britain’s AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.

AstraZeneca says COVID-19 vaccine candidate is 70% effective

The Oxford University and British pharmaceutical giant AstraZeneca have announced on Monday that their vaccine for the novel coronavirus could be around 70% effective under one dosing regimen.

Oxford-AstraZeneca COVID-19 vaccine is 70% effective

This was the first indication that the US trial will remain on hold until the U.S. Food and Drug Administration and a safety panel investigate the case.

What's the status of Oxford-AstraZeneca trials in US; Detailed report

After it "paused" its clinical trial over the vaccine this week, AstraZeneca's CEO Pascal Soriot said today that a vaccine was still possible by the "end of this year, early next year".

Could still have a vaccine by the end of the year, early next year: AstraZeneca CEO

Pharmaceuticals giant AstraZeneca on Tuesday said that it had to "voluntarily paused" a randomized clinical trial of its coronavirus vaccine. The company called it a routine action after a volunteer developed an unexplained illness.

AstraZeneca 'voluntarily pauses' clinical trials for Oxford's COVID-19 vaccine after unexplained illness

AstraZeneca on Tuesday said that it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses.

AstraZeneca conducts clinical trials of COVID-19 drug

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China. Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca.

AstraZeneca signs first deal with Chinese firm to produce COVID-19 vaccine